Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
The DOI matches its Crossref record; 416 of the 416 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. PARTICIPANTS: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. EVIDENCE: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. CONSENSUS PROCESS: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. CONCLUSIONS: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have not associated HRT in women 40-49 years with increased risk of breast cancer (161), and there is no evidence that estrogen replacement in women with premature ovarian failure relates to a higher risk of breast cancer ( 162).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [162]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · cited 3×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
Background2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in development and implementation of evidence-based guidelines (1).”
Method2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534 · cited 2×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
BackgroundClinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149 · cited 2×
“Recent guidelines address bonespecific therapies (43).”
BackgroundWriting Group Members, Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S. M., Ho, M., Howard, V., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.187998 · Cited by 3,711
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Mosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820faaf8 · Cited by 2,143
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741 · cited 35×
“Lung cancer In the 50- to 59-year age group in the WHI study, the incidence of lung cancer was not significantly increased or decreased in either treatment arm (44).”
BackgroundInfluentialHarlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012) · Menopause · doi:10.1097/gme.0b013e31824d8f40 · Cited by 1,705 · cited 3×
“Menopausal transition (or perimenopause) An interval preceding the menopause characterized by variations in menstrual cycle length and bleeding pattern, mood shifts, vasomotor, and vaginal symptoms and with rising FSH levels and falling anti-Mullerian hormone and inhibin B levels, which starts during the late reproduc…”
BackgroundManson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., et al. (2013) · JAMA · doi:10.1001/jama.2013.278040 · Cited by 1,650
A breast cancer prediction model incorporating familial and personal risk factors
Tyrer, J., Duffy, S. W., & Cuzick, J. (2004) · Statistics in Medicine · doi:10.1002/sim.1668 · Cited by 1,345
Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., de Villiers, T. J., & for the STRAW + 10 Collaborative Group (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3362 · Cited by 1,325
Breast cancer and hormone-replacement therapy: the Million Women Study
Beral, V., Banks, E., Reeves, G., & Bull, D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14596-5 · Cited by 1,273
Metabolic Syndrome and Risk of Cancer
Esposito, K., Chiodini, P., Colao, A., Lenzi, A., & Giugliano, D. (2012) · Diabetes Care · doi:10.2337/dc12-0336 · Cited by 1,209
Postmenopausal Hormone Therapy and Mortality
Grodstein, F., Stampfer, M. J., Colditz, G. A., Willett, W. C., Manson, J. E., Joffe, M., Rosner, B., Fuchs, C., Hankinson, S. E., Hunter, D. J., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706193362501 · Cited by 1,184
Nelson, L. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0808697 · Cited by 1,158 · cited 1×
“POI Loss of ovarian function before the age of 40 y with waxing and waning course and potential resumption of menses, conception, and pregnancy (320).”
BackgroundDuration of Menopausal Vasomotor Symptoms Over the Menopause Transition
Avis, N. E., Crawford, S. L., Greendale, G., Bromberger, J. T., Everson-Rose, S. A., Gold, E. B., Hess, R., Joffe, H., Kravitz, H. M., Tepper, P. G., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.8063 · Cited by 1,028
Bushnell, C., McCullough, L. D., Awad, I. A., Chireau, M. V., Fedder, W. N., Furie, K. L., Howard, V. J., Lichtman, J. H., Lisabeth, L. D., Piña, I. L., et al. (2014) · Stroke · doi:10.1161/01.str.0000442009.06663.48 · Cited by 941 · cited 2×
“To decrease morbidity and mortality from CVD and cancer and maintain QOL, optimizing diet and exercise to maintain healthy weight are important measures, as are counseling regarding alcohol use and smoking cessation and identifying and treating hypertension, glucose intolerance, and dyslipidemias (40, 41).”
BackgroundRaz, R., & Stamm, W. E. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291102 · Cited by 928 · cited 1×
“prevent recurrent urinary tract infections (268, 269) and”
BackgroundA prospective population-based study of menopausal symptoms
Dennerstein, L. (2000) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(00)00930-3 · Cited by 883 · cited 10×
“The first compared the effect of oral vs transdermal es3978 Stuenkel et al Guideline on Menopause J Clin Endocrinol Metab, November 2015, 100(11):3975–4011”
BackgroundInfluentialCanonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., Trillot, N., Barrellier, M.-T., Wahl, D., Emmerich, J., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.642280 · Cited by 864 · cited 1×
“are supported by observational studies (106, 108, 109).”
MethodEspeland, M. A. (2004) · JAMA · doi:10.1001/jama.291.24.2959 · Cited by 795
The 2012 Hormone Therapy Position Statement of The North American Menopause Society
(2012) · Menopause · doi:10.1097/gme.0b013e31824b970a · Cited by 785
Schierbeck, L. L., Rejnmark, L., Tofteng, C. L., Stilgren, L., Eiken, P., Mosekilde, L., Kober, L., & Jensen, J.-E. B. (2012) · BMJ · doi:10.1136/bmj.e6409 · Cited by 747 · cited 2×
“A randomized osteoporosis trial that did not have CHD as a predefined primary endpoint reported that 10 years of MHT treatment in women 50 years old at study onset was associated with the reduction of a composite safety endpoint (death, hospital admission for MI, or heart failure) (103).”
BackgroundEffects of estrogen on memory function in surgically menopausal women
Phillips, S. (1992) · Psychoneuroendocrinology · doi:10.1016/0306-4530(92)90007-t · Cited by 741
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Estrogen Therapy and Coronary-Artery Calcification
Manson, J. E., Allison, M. A., Rossouw, J. E., Carr, J. J., Langer, R. D., Hsia, J., Kuller, L. H., Cochrane, B. B., Hunt, J. R., Ludlam, S. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071513 · Cited by 711 · cited 1×
“Composite outcomes, including revascularization (98) and coronary artery calcium scores (99), were lower with ET than with placebo.”
BackgroundFournier, A., Berrino, F., & Clavel-Chapelon, F. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9523-x · Cited by 693 · cited 3×
“However, observational data suggest that progesterone or dydrogesterone (5, 89) may be associated with a lower risk, but further studies are required to confirm this.”
BackgroundResultPortman, D. J., & Gass, M. L. S. (2014) · Menopause · doi:10.1097/gme.0000000000000329 · Cited by 688 · cited 2×
“2014;21:1063–1068 (37), with permission.”
BackgroundPostmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N., Braunstein, G. D., Burger, H. G., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 680 · cited 19×
“An accepted philosophy is that a fully informed patient should be empowered to make a decision that best balances individual QOL benefits against potential health risks (21).”
BackgroundResultInfluentialSelf-citationEstrogen plus Progestin and Colorectal Cancer in Postmenopausal Women
Chlebowski, R. T., Wactawski-Wende, J., Ritenbaugh, C., Hubbell, F. A., Ascensao, J., Rodabough, R. J., Rosenberg, C. A., Taylor, V. M., Harris, R., Chen, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032071 · Cited by 669
Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups
Avis, N. E., Stellato, R., Crawford, S., Bromberger, J., Ganz, P., Cain, V., & Kagawa-Singer, M. (2001) · Social Science & Medicine · doi:10.1016/s0277-9536(00)00147-7 · Cited by 643
Kanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Grady, D., Bittner, V., Cauley, J. A., & Barrett-Connor, E. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00005 · Cited by 633
Estrogen plus progestin and risk of venous thrombosis
Cushman, M. (2004) · JAMA · doi:10.1001/jama.292.13.1573 · Cited by 632
Hormone therapy for preventing cardiovascular disease in post-menopausal women
Boardman, H. M., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., Gabriel Sanchez, R., & Knight, B. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002229.pub4 · Cited by 612 · cited 1×
“95) of all-cause mortality in women starting MHT 10 years since menopause (or age 60) (127).”
BackgroundConjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative
Hsia, J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.357 · Cited by 610 · cited 1×
“Composite outcomes, including revascularization (98) and coronary artery calcium scores (99), were lower with ET than with placebo.”
BackgroundRisk of Menopause During the First Year After Breast Cancer Diagnosis
Goodwin, P. J., Ennis, M., Pritchard, K. I., Trudeau, M., & Hood, N. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2365 · Cited by 606 · cited 2×
“amenorrhea (22), depending on the age of the woman and”
BackgroundMiller, V. T., LaRosa, J. C., Barnabei, V. M., Kessler, C. M., Levin, G., Smith-Roth, A., Griffin, M. E., Stoy, D. B., Bush, T. L., Zacur, H. A., et al. (1995) · JAMA · doi:10.1001/jama.273.3.199 · Cited by 601
Local oestrogen for vaginal atrophy in postmenopausal women
Lethaby, A., Ayeleke, R. O., & Roberts, H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001500.pub3 · Cited by 601 · cited 5×
“(261) compared 19 efficacy trials and found that all prod-”
BackgroundInfluentialfor the Women’s Health Initiative Investigators, Margolis, K. L., Bonds, D. E., Rodabough, R. J., Tinker, L., Phillips, L. S., Allen, C., Bassford, T., Burke, G., Torrens, J., et al. (2004) · Diabetologia · doi:10.1007/s00125-004-1448-x · Cited by 599
HORMONE REPLACEMENT THERAPY, HEART DISEASE, AND OTHER CONSIDERATIONS
Barrett-Connor, E., & Grady, D. (1998) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.19.1.55 · Cited by 590 · cited 1×
“Observational studies of ET suggest the potential for CHD benefit in some women, although a number of biases might have contributed to those conclusions (100).”
ResultLong term hormone therapy for perimenopausal and postmenopausal women
Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J. A., & Lamberts, Q. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub2 · Cited by 582
Stefanick, M. L., Anderson, G. L., Margolis, K. L., Hendrix, S. L., Rodabough, R. J., Paskett, E. D., Lane, D. S., Hubbell, F. A., Assaf, A. R., Sarto, G. E., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1647 · Cited by 571 · cited 1×
“On this basis, the excess or attributable risk should increase in women at higher categories of risk (90, 152).”
BackgroundCanonico, M., Plu-Bureau, G., Lowe, G. D. O., & Scarabin, P.-Y. (2008) · BMJ · doi:10.1136/bmj.39555.441944.be · Cited by 569 · cited 1×
“tional studies (108–112) and meta-analyses (4, 113) sug-”
Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women
Chlebowski, R. T., Anderson, G. L., Gass, M., Lane, D. S., Aragaki, A. K., Kuller, L. H., Manson, J. E., Stefanick, M. L., Ockene, J., Sarto, G. E., et al. (2010) · JAMA · doi:10.1001/jama.2010.1500 · Cited by 567 · cited 2×
“On this basis, the excess or attributable risk should increase in women at higher categories of risk (90, 152).”
BackgroundEstrogens and Endometrial Cancer in a Retirement Community
Mack, T. M., Pike, M. C., Henderson, B. E., Pfeffer, R. I., Gerkins, V. R., Arthur, M., & Brown, S. E. (1976) · New England Journal of Medicine · doi:10.1056/nejm197606032942304 · Cited by 557 · cited 1×
“Endometrial cancer Unopposed ET increases the risk of endometrial hyperplasia and cancer (38, 65, 66), whereas concurrent progestogen therapy (Table 5) for at least 12 days per month reduces this risk (18, 44, 67) and is recommended for all women with a uterus.”
BackgroundKronenberg, F., & Fugh-Berman, A. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-10-200211190-00009 · Cited by 554
Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes
MacLennan, A. H., Broadbent, J. L., Lester, S., & Moore, V. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002978.pub2 · Cited by 543 · cited 1×
“In a dose-dependent manner, MHT reduces hot flash frequency by approximately 75% and severity by 87%, compared with 50% with placebo (38, 45, 46).”
BackgroundWoods, N. F., & Mitchell, E. S. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.031 · Cited by 529
Effects of Estrogen With and Without Progestin on Urinary Incontinence
Hendrix, S. L. (2005) · JAMA · doi:10.1001/jama.293.8.935 · Cited by 509
Stearns, V., Beebe, K. L., Iyengar, M., & Dube, E. (2003) · JAMA · doi:10.1001/jama.289.21.2827 · Cited by 496
Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes
Loprinzi, C. L., Sloan, J. A., Perez, E. A., Quella, S. K., Stella, P. J., Mailliard, J. A., Halyard, M. Y., Pruthi, S., Novotny, P. J., & Rummans, T. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1578 · Cited by 473
Collaborative Group on Epidemiological Studies of Ovarian Cancer (2015) · The Lancet · doi:10.1016/s0140-6736(14)61687-1 · Cited by 472
Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models
Amir, E., Freedman, O. C., Seruga, B., & Evans, D. G. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq088 · Cited by 464 · cited 3×
“For women with strong family histories of breast cancer, several other methods are available (155).”
BackgroundMethodThe Effects of Tibolone in Older Postmenopausal Women
Cummings, S. R., Ettinger, B., Delmas, P. D., Kenemans, P., Stathopoulos, V., Verweij, P., Mol-Arts, M., Kloosterboer, L., Mosca, L., Christiansen, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800743 · Cited by 457 · cited 3×
“The incidence of breast tenderness is low (around 3%), (201, 202), and neither mammographic density nor invasive breast cancer was increased; however, the risk of colon cancer was decreased (199, 201).”
BackgroundFactors Related to Age at Natural Menopause: Longitudinal Analyses From SWAN
Gold, E. B., Crawford, S. L., Avis, N. E., Crandall, C. J., Matthews, K. A., Waetjen, L. E., Lee, J. S., Thurston, R., Vuga, M., & Harlow, S. D. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws421 · Cited by 429
Prevalence of hot flushes and night sweats around the world: a systematic review
Freeman, E. W., & Sherif, K. (2007) · Climacteric · doi:10.1080/13697130601181486 · Cited by 411
Portman, D. J., Gass, M. L. S., & Panel, O. B. O. T. V. A. T. C. C. (2014) · Climacteric · doi:10.3109/13697137.2014.946279 · Cited by 407
Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.
Barton, D. L., Loprinzi, C. L., Quella, S. K., Sloan, J. A., Veeder, M. H., Egner, J. R., Fidler, P., Stella, P. J., Swan, D. K., Vaught, N. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.495 · Cited by 403
Oestrogen therapy for urinary incontinence in post-menopausal women
Cody, J. D., Jacobs, M. L., Richardson, K., Moehrer, B., & Hextall, A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001405.pub3 · Cited by 391
CARDOZO, L. (1998) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(98)00175-6 · Cited by 388 · cited 1×
“recurrent urinary tract infections (47, 48).”
Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study
Renoux, C., Dell'Aniello, S., Garbe, E., & Suissa, S. (2010) · BMJ · doi:10.1136/bmj.c2519 · Cited by 386 · cited 1×
“higher dose transdermal or oral therapies (4, 105).”
BackgroundRance, N. E., Dacks, P. A., Mittelman-Smith, M. A., Romanovsky, A. A., & Krajewski-Hall, S. J. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.003 · Cited by 380 · cited 1×
“VMS appear to involve the central nervous system (32) because: 1) hot flashes occur simultaneously with, but are not caused by, LH pulses (33, 34); and 2) research has shown an association with the neuroregulators kisspeptin, neurokinin B, and dynorphin (35).”
BackgroundQuella, S. K., Loprinzi, C. L., Barton, D. L., Knost, J. A., Sloan, J. A., LaVasseur, B. I., Swan, D., Krupp, K. R., Miller, K. D., & Novotny, P. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1068 · Cited by 372
Anderson, G. L., Chlebowski, R. T., Aragaki, A. K., Kuller, L. H., Manson, J. E., Gass, M., Bluhm, E., Connelly, S., Hubbell, F. A., Lane, D., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70075-x · Cited by 364 · cited 1×
“In women in the WHI ages 50 to 59 or 10 years after menopause onset, CEE did not increase risk (44, 84).”
BackgroundMurkies, A. L., Wilcox, G., & Davis, S. R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4577 · Cited by 355
Self-citationSTRAW+10のエグゼクティブサマリー: 生殖年齢の評価における未完成の課題に対する取り組み
Sioban, D. H., Gass, M. L. S., Janet, E. H., ROGER, L. J., Pauline, M. F., Robert, W. M., Sherry, S., Patrick, M., & Tobie, J. (2012) · The Journal of Clinical Endocrinology & Metabolism · Cited by 354
Oestrogens for preventing recurrent urinary tract infection in postmenopausal women
Perrotta, C., Aznar, M., Mejia, R., Albert, X., & Ng, C. W. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005131.pub2 · Cited by 350
Scarabin, P.-Y., Alhenc-Gelas, M., Plu-Bureau, G., Taisne, P., Agher, R., & Aiach, M. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.3071 · Cited by 348 · cited 1×
“The primary advantage of transdermal ET is to alleviate the firstpass hepatic metabolic effect (166) of oral estrogens resulting in a procoagulant effect and increases in SHBG, thyroid-binding globulin, cortisol-binding globulin (167, 168), triglycerides, and markers of inflammation such as C-reactive protein (167, 16…”
BackgroundUtian, W. H., Shoupe, D., Bachmann, G., Pinkerton, J. V., & Pickar, J. H. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(01)01791-5 · Cited by 348 · cited 1×
“In a dose-dependent manner, MHT reduces hot flash frequency by approximately 75% and severity by 87%, compared with 50% with placebo (38, 45, 46).”
BackgroundSelf-citationChen, J., Pee, D., Ayyagari, R., Graubard, B., Schairer, C., Byrne, C., Benichou, J., & Gail, M. H. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj332 · Cited by 346
Harman, S. M., Black, D. M., Naftolin, F., Brinton, E. A., Budoff, M. J., Cedars, M. I., Hopkins, P. N., Lobo, R. A., Manson, J. E., Merriam, G. R., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0353 · Cited by 344 · cited 1×
“ter 4 years of therapy (104) but may have been underpow-”
BackgroundBachmann, G. A., Goldstein, S. R., LIU, J. H., Martens, M. G., Pace, D. T., & Pinkerton, J. V. (2013) · Cited by 339
Self-citationKenemans, P., Bundred, N. J., Foidart, J.-M., Kubista, E., von Schoultz, B., Sismondi, P., Vassilopoulou-Sellin, R., Yip, C. H., Egberts, J., Mol-Arts, M., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70341-3 · Cited by 337
Eriksen, B. C. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70597-1 · Cited by 336 · cited 1×
“prevent recurrent urinary tract infections (268, 269) and”
BackgroundPandya, K. J., Morrow, G. R., Roscoe, J. A., Zhao, H., Hickok, J. T., Pajon, E., Sweeney, T. J., Banerjee, T. K., & Flynn, P. J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67215-7 · Cited by 333
Cognitive function in nondemented older women who took estrogen after menopause
Jacobs, D. M., Tang, M.-X., Stern, Y., Sano, M., Marder, K., Bell, K. L., Schofield, P., Dooneief, G., Gurland, B., & Mayeux, R. (1998) · Neurology · doi:10.1212/wnl.50.2.368 · Cited by 332
Barnabei, V. M., Cochrane, B. B., Aragaki, A. K., Nygaard, I., Williams, R. S., McGovern, P. G., Young, R. L., Wells, E. C., OʼSullivan, M. J., Chen, B., et al. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000158120.47542.18 · Cited by 320
Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial
Guttuso, T. (2003) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(02)02712-6 · Cited by 313
Upmalis, D. H., Lobo, R., Bradley, L., Warren, M., Cone, F. L., & Lamia, C. A. (2000) · Menopause · doi:10.1097/00042192-200007040-00005 · Cited by 307
Newton, K. M., Reed, S. D., LaCroix, A. Z., Grothaus, L. C., Ehrlich, K., & Guiltinan, J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-12-200612190-00003 · Cited by 307
Visvanathan, K., Hurley, P., Bantug, E., Brown, P., Col, N. F., Cuzick, J., Davidson, N. E., DeCensi, A., Fabian, C., Ford, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3122 · Cited by 307 · cited 2×
“a Categories here are newly defined for these guidelines and based on recommendations published for use of antiestrogens for breast cancer prevention (126, 153, 322, 323).”
BackgroundMethodEffect of Estrogen Therapy on Gallbladder Disease
Cirillo, D. J. (2005) · JAMA · doi:10.1001/jama.293.3.330 · Cited by 304
Swiglo, B. A., Murad, M. H., Schünemann, H. J., Kunz, R., Vigersky, R. A., Guyatt, G. H., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1907 · Cited by 302 · cited 1×
“A detailed description of the grading scheme has been published elsewhere (2).”
MethodSelf-citationBygdeman, M., & Swahn, M. L. (1996) · Maturitas · doi:10.1016/0378-5122(95)00955-8 · Cited by 299
Commonly Used Types of Postmenopausal Estrogen for Treatment of Hot Flashes: Scientific Review
Nelson, H. D. (2004) · JAMA · doi:10.1001/jama.291.13.1610 · Cited by 296 · cited 1×
“Cutaneous and transdermal estradiol, administered via percutaneous gels, sprays, emulsions, or transdermal patches, have a similar efficacy as oral ET in reducing climacteric symptoms and are easily tailored to the individual (164, 165).”
BackgroundMortality associated with hormone replacement therapy in younger and older women: A meta-analysis
Salpeter, S. R., Walsh, J. M. E., Greyber, E., Ormiston, T. M., & Salpeter, E. E. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30281.x · Cited by 292 · cited 1×
“This is consistent with meta-analyses that reported a 30–40% mortality reduction (131, 132).”
Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy
Beral, V., Reeves, G., Bull, D., Green, J., & Collaborators, F. T. M. W. S. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq527 · Cited by 292 · cited 1×
“The statistically significant 21% reduction of invasive breast cancer in the 13-year cumulative follow-up of all women in the estrogen-alone arm of the WHI was of similar magnitude in each age group (44), but some analyses have suggested less reduction or an increase in risk among women starting ET close to menopause…”
ResultHøibraaten, E., Qvigstad, E., Arnesen, H., Larsen, S. U., Wickström, E., & Sandset, P. (2000) · PubMed · Cited by 282
Prevention of diseases after menopause
Lobo, R. A., Davis, S. R., De Villiers, T. J., Gompel, A., Henderson, V. W., Hodis, H. N., Lumsden, M. A., Mack, W. J., Shapiro, S., & Baber, R. J. (2014) · Climacteric · doi:10.3109/13697137.2014.933411 · Cited by 279
Self-citationLong term hormone therapy for perimenopausal and postmenopausal women
Marjoribanks, J., Farquhar, C., Roberts, H., & Lethaby, A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub4 · Cited by 278
Canonico, M., Fournier, A., Carcaillon, L., Olié, V., Plu-Bureau, G., Oger, E., Mesrine, S., Boutron-Ruault, M.-C., Clavel-Chapelon, F., & Scarabin, P.-Y. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.196022 · Cited by 272
Vehkavaara, S., Silveira, A., Hakala-Ala-Pietilä, T., Virkamäki, A., Hovatta, O., Hamsten, A., Taskinen, M.-R., & Yki-Järvinen, H. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615643 · Cited by 270 · cited 1×
“The primary advantage of transdermal ET is to alleviate the firstpass hepatic metabolic effect (166) of oral estrogens resulting in a procoagulant effect and increases in SHBG, thyroid-binding globulin, cortisol-binding globulin (167, 168), triglycerides, and markers of inflammation such as C-reactive protein (167, 16…”
BackgroundTice, J. A., Ettinger, B., Ensrud, K., Wallace, R., Blackwell, T., & Cummings, S. R. (2003) · JAMA · doi:10.1001/jama.290.2.207 · Cited by 268
Increased need for thyroxine in women with hypothyroidism during estrogen therapy
Arafah, B. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442302 · Cited by 267 · cited 4×
“MHT discontinuation may result in symptoms of VVA (Section 5.0), and when oral therapy isdiscontinued, glucose, cholesterol, triglycerides, calcium, and TSH (209) levels may change.”
BackgroundInfluentialMenopausal flushes: a neuroendocrine link with pulsatile luteinizing hormone secretion
Casper, R. F., Yen, S. S. C., & Wilkes, M. M. (1979) · Science · doi:10.1126/science.462193 · Cited by 267 · cited 1×
“VMS appear to involve the central nervous system (32) because: 1) hot flashes occur simultaneously with, but are not caused by, LH pulses (33, 34); and 2) research has shown an association with the neuroregulators kisspeptin, neurokinin B, and dynorphin (35).”
BackgroundVan Patten, C. L., Olivotto, I. A., Chambers, G. K., Gelmon, K. A., Hislop, T. G., Templeton, E., Wattie, A., & Prior, J. C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1449 · Cited by 265
Black cohosh (Cimicifuga spp.) for menopausal symptoms
Leach, M., & Moore, V. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007244.pub2 · Cited by 262
Lobo, R. A., Pinkerton, J. V., Gass, M. L. S., Dorin, M. H., Ronkin, S., Pickar, J. H., & Constantine, G. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.03.113 · Cited by 254 · cited 3×
“there was no additive effect on VTE when BZA was combined with CEE, although adequately powered studies are necessary (181).”
BackgroundSelf-citationUnopposed Estrogen Therapy and the Risk of Invasive Breast Cancer
Chen, W. Y., Manson, J. E., Hankinson, S. E., Rosner, B., Holmes, M. D., Willett, W. C., & Colditz, G. A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.9.1027 · Cited by 251
Sherwin, B. B. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3771-3 · Cited by 247
Portman, D. J., Bachmann, G. A., & Simon, J. A. (2013) · Menopause · doi:10.1097/gme.0b013e318279ba64 · Cited by 246
Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women: A Randomized Controlled Trial
Freeman, E. W. (2011) · JAMA · doi:10.1001/jama.2010.2016 · Cited by 245
Dodin, S., Lemay, A., Jacques, H., Légaré, F., Forest, J.-C., & Mâsse, B. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1148 · Cited by 244
Nedrow, A., Miller, J., Walker, M., Nygren, P., Huffman, L. H., & Nelson, H. D. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.14.1453 · Cited by 242
Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies
Maki, P. M. (2013) · Menopause · doi:10.1097/gme.0b013e3182960cf8 · Cited by 242 · cited 1×
“Dementia Observational studies suggest a possible benefit of MHT if started in younger women closer to menopause (133), as opposed to the detrimental effects reported in clinical trials when MHT is initiated in women 65 years old (134).”
BackgroundUse of alternative therapies for menopause symptoms: results of a population-based survey
Newton, K. (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(02)02005-7 · Cited by 241
Anderson, G. L., Chlebowski, R. T., Rossouw, J. E., Rodabough, R. J., McTiernan, A., Margolis, K. L., Aggerwal, A., Curb, J. D., Hendrix, S. L., Hubbell, F. A., et al. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.05.004 · Cited by 239 · cited 1×
“It should be noted that the original WHI study did not report any increase overall in women who had not previously used MHT (hormone naive), but data on this issue are not available for women ages 50 to 59 or 10 years postmenopausal (18, 91), and there are no reported follow-up data for the hormone-naive women.”
BackgroundBarakat, R. R., Bundy, B. N., Spirtos, N. M., Bell, J., & Mannel, R. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8464 · Cited by 238
Bachmann, G. A., & Komi, J. O. (2010) · Menopause · doi:10.1097/gme.0b013e3181c1ac01 · Cited by 235
Lindsay, R., Gallagher, J. C., Kagan, R., Pickar, J. H., & Constantine, G. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.02.093 · Cited by 234 · cited 1×
“Bone loss at the lumbar spine and hip was prevented in postmenopausal women at risk for osteoporosis (182), as reflected by reduction of serum bone turnover markers and enhancement of bone mineral density vs placebo (180, 181).”
BackgroundBenefits and Risks of Postmenopausal Hormone Therapy When It Is Initiated Soon After Menopause
Prentice, R. L., Manson, J. E., Langer, R. D., Anderson, G. L., Pettinger, M., Jackson, R. D., Johnson, K. C., Kuller, L. H., Lane, D. S., Wactawski-Wende, J., et al. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp115 · Cited by 234 · cited 2×
“Observational studies also report a greater risk when EPT is started close to menopause (79, 85, 93) and with continuous rather than with cyclic regimens (78, 82, 94).”
BackgroundResultEvans, M. L., Pritts, E., Vittinghoff, E., McClish, K., Morgan, K. S., & Jaffe, R. B. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000147840.06947.46 · Cited by 231
Comparative study: Replens versus local estrogen in menopausal women
Nachtigall, L. E. (1994) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56474-7 · Cited by 229
NEUROENDOCRINOLOGY OF MENOPAUSAL FLUSHES: AN HYPOTHESIS OF FLUSH MECHANISM
CASPER, R. F., & YEN, S. S. C. (1985) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1985.tb03243.x · Cited by 228 · cited 2×
“Shivering may occur to restore the core temperature (36).”
BackgroundExercise for vasomotor menopausal symptoms
Daley, A., Stokes-Lampard, H., Thomas, A., & MacArthur, C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006108.pub4 · Cited by 225
Behavioral treatment of menopausal hot flushes: Evaluation by ambulatory monitoring
Freedman, R. R., & Woodward, S. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(11)91425-2 · Cited by 225
Stearns, V., Slack, R., Greep, N., Henry-Tilman, R., Osborne, M., Bunnell, C., Ullmer, L., Gallagher, A., Cullen, J., Gehan, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.081 · Cited by 224
Breast Cancer Risk by Breast Density, Menopause, and Postmenopausal Hormone Therapy Use
Kerlikowske, K., Cook, A. J., Buist, D. S. M., Cummings, S. R., Vachon, C., Vacek, P., & Miglioretti, D. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4770 · Cited by 224
Gabapentin, Estrogen, and Placebo for Treating Hot Flushes: A Randomized Controlled Trial
Reddy, S. Y., Warner, H., Guttuso, T., Messing, S., DiGrazio, W., Thornburg, L., & Guzick, D. S. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000222383.43913.ed · Cited by 223 · cited 1×
“Relative efficacy of nonhormonal prescription therapies vs estrogens A limited number of head-to-head RCTs have compared varying estrogen doses, preparations, and routes of administration with nonhormonal agents (213, 240, 244).”
BackgroundEspeland, M. A., Rapp, S. R., Shumaker, S. A., Brunner, R., Manson, J. E., Sherwin, B. B., Hsia, J., Margolis, K. L., Hogan, P. E., Wallace, R., et al. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000140471.21348.f1 · Cited by 222 · cited 1×
“Some studies of postmenopausal women treated with estradiol reported an improvement in verbal memory and executive function (135–138), whereas other studies did not associate CEE therapy with cognitive improvement (139, 140).”
ResultDuijts, S. F. A., van Beurden, M., Oldenburg, H. S. A., Hunter, M. S., Kieffer, J. M., Stuiver, M. M., Gerritsma, M. A., Menke-Pluymers, M. B. E., Plaisier, P. W., Rijna, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.8525 · Cited by 220
Phytoestrogens for vasomotor menopausal symptoms
Lethaby, A., Marjoribanks, J., Kronenberg, F., Roberts, H., Eden, J., & Brown, J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001395.pub3 · Cited by 217
Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus
Curb, J. D., Prentice, R. L., Bray, P. F., Langer, R. D., Van Horn, L., Barnabei, V. M., Bloch, M. J., Cyr, M. G., Gass, M., Lepine, L., et al. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.772 · Cited by 217
Hot flashes: behavioral treatments, mechanisms, and relation to sleep
Freedman, R. R. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.046 · Cited by 216 · cited 3×
“VMS appear to involve the central nervous system (32) because: 1) hot flashes occur simultaneously with, but are not caused by, LH pulses (33, 34); and 2) research has shown an association with the neuroregulators kisspeptin, neurokinin B, and dynorphin (35).”
Background(2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.06.061 · Cited by 214
Bonds, D. E., Lasser, N., Qi, L., Brzyski, R., Caan, B., Heiss, G., Limacher, M. C., Liu, J. H., Mason, E., Oberman, A., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0096-0 · Cited by 213
Smith, S. C., Jr. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/tvax-0z76 · Cited by 213
Efficacy and Safety of Isopropanolic Black Cohosh Extract for Climacteric Symptoms
Osmers, R., Friede, M., Liske, E., Schnitker, J., Freudenstein, J., & Henneicke-von Zepelin, H.-H. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000158865.98070.89 · Cited by 212
SWEETLAND, S., BERAL, V., BALKWILL, A., LIU, B., BENSON, V. S., CANONICO, M., GREEN, J., & REEVES, G. K. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04919.x · Cited by 208 · cited 1×
“are supported by observational studies (106, 108, 109).”
MethodHormone replacement therapy and the risk of venous thromboembolism: a population-based study
RENOUX, C., Dell'ANIELLO, S., & SUISSA, S. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03839.x · Cited by 208 · cited 1×
“In an observational study (110), tibolone did not increase the risk of thrombosis.”
BackgroundIncreasing Incidence of Endometrial Cancer in the United States
Weiss, N. S., Szekely, D. R., & Austin, D. F. (1976) · New England Journal of Medicine · doi:10.1056/nejm197606032942303 · Cited by 208 · cited 1×
“Endometrial cancer Unopposed ET increases the risk of endometrial hyperplasia and cancer (38, 65, 66), whereas concurrent progestogen therapy (Table 5) for at least 12 days per month reduces this risk (18, 44, 67) and is recommended for all women with a uterus.”
BackgroundClinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial
Elkins, G. R., Fisher, W. I., Johnson, A. K., Carpenter, J. S., & Keith, T. Z. (2013) · Menopause · doi:10.1097/gme.0b013e31826ce3ed · Cited by 208
Ayers, B., Smith, M., Hellier, J., Mann, E., & Hunter, M. S. (2012) · Menopause · doi:10.1097/gme.0b013e31823fe835 · Cited by 207
Chlebowski, R. T., Manson, J. E., Anderson, G. L., Cauley, J. A., Aragaki, A. K., Stefanick, M. L., Lane, D. S., Johnson, K. C., Wactawski-Wende, J., Chen, C., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt043 · Cited by 205 · cited 1×
“Observational studies also report a greater risk when EPT is started close to menopause (79, 85, 93) and with continuous rather than with cyclic regimens (78, 82, 94).”
BackgroundGuideline panels should not GRADE good practice statements
Guyatt, G. H., Schünemann, H. J., Djulbegovic, B., & Akl, E. A. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.12.011 · Cited by 201 · cited 1×
“The intention of these statements is to draw attention and remind providers of these principles, and these statements should not be considered as graded recommendations (3).”
BackgroundKalantaridou, S. N., Davis, S. R., & Nelson, L. M. (1998) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70051-7 · Cited by 201
Self-citationBayesian Meta-analysis of Hormone Therapy and Mortality in Younger Postmenopausal Women
Salpeter, S. R., Cheng, J., Thabane, L., Buckley, N. S., & Salpeter, E. E. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.05.021 · Cited by 201 · cited 1×
“This is consistent with meta-analyses that reported a 30–40% mortality reduction (131, 132).”
ResultStraczek, C., Oger, E., Yon de Jonage-Canonico, M. B., Plu-Bureau, G., Conard, J., Meyer, G., Alhenc-Gelas, M., Lévesque, H., Trillot, N., Barrellier, M.-T., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.565556 · Cited by 200
LH, FSH AND SKIN TEMPERATURE DURING THE MENOPAUSAL HOT FLAS
Tataryn, I. V., Meldrum, D. R., Lu, K. H., Fruraar, A. M., & Judd, H. L. (1979) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-49-1-152 · Cited by 200 · cited 1×
“VMS appear to involve the central nervous system (32) because: 1) hot flashes occur simultaneously with, but are not caused by, LH pulses (33, 34); and 2) research has shown an association with the neuroregulators kisspeptin, neurokinin B, and dynorphin (35).”
BackgroundOral Medroxyprogesterone in the Treatment of Postmenopausal Symptoms
Schiff, I. (1980) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1980.03310130021021 · Cited by 199 · cited 1×
“In RCTs, oral synthetic progestogens (Table 5) (174, 175) and micronized progesterone (176) were effective.”
BackgroundSherwin, B. B. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.7.2545 · Cited by 198
Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland
Soini, T., Hurskainen, R., Grénman, S., Mäenpää, J., Paavonen, J., & Pukkala, E. (2014) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000356 · Cited by 197 · cited 1×
“The levonorgestrel intrauterine device minimizes systemic progestogen absorption, but increased blood levels do occur, and one observational study reported higher breast cancer incidence (173).”
Background(2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200211000-00019 · Cited by 196
Taku, K., Melby, M. K., Kronenberg, F., Kurzer, M. S., & Messina, M. (2012) · Menopause · doi:10.1097/gme.0b013e3182410159 · Cited by 195
Adverse events reported by postmenopausal women in controlled trials with raloxifene
Davies, G. (1999) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(98)00476-1 · Cited by 195
Grodstein, F., Manson, J. E., Stampfer, M. J., & Rexrode, K. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.861 · Cited by 192
Short-term and long-term effects of tibolone in postmenopausal women
Formoso, G., Perrone, E., Maltoni, S., Balduzzi, S., Wilkinson, J., Basevi, V., Marata, A. M., Magrini, N., D'Amico, R., Bassi, C., et al. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008536.pub3 · Cited by 192
Kagan, R., Williams, R. S., Pan, K., Mirkin, S., & Pickar, J. H. (2010) · Menopause · doi:10.1097/gme.0b013e3181b7c65f · Cited by 191 · cited 1×
“Treating postmenopausal women ages 40 to 65 with VVA at baseline (183) improved vaginal maturation at 12 weeks (181).”
BackgroundJoffe, H., Guthrie, K. A., LaCroix, A. Z., Reed, S. D., Ensrud, K. E., Manson, J. E., Newton, K. M., Freeman, E. W., Anderson, G. L., Larson, J. C., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.1891 · Cited by 191 · cited 2×
“However, when these and other published data are taken into account (213, 217, 236, 245), the limited evidence available suggests that standard-dose MHT is more effective than nonhormonal agents.”
BackgroundFreedman, A. N., Yu, B., Gail, M. H., Costantino, J. P., Graubard, B. I., Vogel, V. G., Anderson, G. L., & McCaskill-Stevens, W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0258 · Cited by 191 · cited 1×
“a Categories here are newly defined for these guidelines and based on recommendations published for use of antiestrogens for breast cancer prevention (126, 153, 322, 323).”
MethodMindfulness training for coping with hot flashes: results of a randomized trial
Carmody, J. F., Crawford, S., Salmoirago-Blotcher, E., Leung, K., Churchill, L., & Olendzki, N. (2011) · Menopause · doi:10.1097/gme.0b013e318204a05c · Cited by 188
Hammar, M., Christau, S., Nathorst‐Böös, J., Rud, T., & Garre, K. (1998) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1998.tb10237.x · Cited by 187 · cited 1×
“The incidence of breast tenderness is low (around 3%), (201, 202), and neither mammographic density nor invasive breast cancer was increased; however, the risk of colon cancer was decreased (199, 201).”
BackgroundBreast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy
Day, S., & Bevers, T. B. (2011) · Breast Diseases: A Year Book Quarterly · doi:10.1016/j.breastdis.2011.10.032 · Cited by 187
Pickar, J. H., Yeh, I.-T., Bachmann, G., & Speroff, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.05.094 · Cited by 186 · cited 1×
“At 2 years, the incidence of neither endometrial hyperplasia nor endometrial cancer was increased (180, 189).”
BackgroundPockaj, B. A., Gallagher, J. G., Loprinzi, C. L., Stella, P. J., Barton, D. L., Sloan, J. A., Lavasseur, B. I., Rao, R. M., Fitch, T. R., Rowland, K. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4296 · Cited by 185
Santen, R. J. (2015) · Climacteric · doi:10.3109/13697137.2014.947254 · Cited by 181 · cited 1×
“as: 1) low, 2) intermediate, and 3) systemic doses (274)”
Self-citationNewer Antidepressants and Gabapentin for Hot Flashes: An Individual Patient Pooled Analysis
Loprinzi, C. L., Sloan, J., Stearns, V., Slack, R., Iyengar, M., Diekmann, B., Kimmick, G., Lovato, J., Gordon, P., Pandya, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6253 · Cited by 179
Levis, S. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.330 · Cited by 179
Clarkson, T. B., Utian, W. H., Barnes, S., Gold, E. B., Basaria, S. S., Asô, T., Kronenberg, F., Frankenfeld, C. L., Cline, J. M., Landgren, B., et al. (2011) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31821fc8e0 · Cited by 175
Loprinzi, C. L., Abu-Ghazaleh, S., Sloan, J. A., vanHaelst-Pisani, C., Hammer, A. M., Rowland, K. M., Law, M., Windschitl, H. E., Kaur, J. S., & Ellison, N. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.969 · Cited by 172
Le Ray, I., Dell’Aniello, S., Bonnetain, F., Azoulay, L., & Suissa, S. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2198-y · Cited by 172
Temporal associations of hot flashes and depression in the transition to menopause
Freeman, E. W., Sammel, M. D., & Lin, H. (2009) · Menopause · doi:10.1097/gme.0b013e3181967e16 · Cited by 171 · cited 1×
“It is less clear whether anxiety, irritability, depression, palpitations, skin dryness, loss of libido, and fatigue can be attributed to menopause (7, 9, 12).”
BackgroundThurston, R. C., Sowers, M. R., Sternfeld, B., Gold, E. B., Bromberger, J., Chang, Y., Joffe, H., Crandall, C. J., Waetjen, L. E., & Matthews, K. A. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp203 · Cited by 168
Loprinzi, C. L., Qin, R., Baclueva, E. P., Flynn, K. A., Rowland, K. M., Graham, D. L., Erwin, N. K., Dakhil, S. R., Jurgens, D. J., & Burger, K. N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5647 · Cited by 165 · cited 1×
“Pregabalin In one 6-week RCT, pregabalin (75–150 mg twice daily) decreased mean hot flash scores by 65 and 71%, compared with 50% by placebo (242), and was reasonably well tolerated.”
BackgroundInfluence of menopause on diabetes and diabetes risk
Szmuilowicz, E. D., Stuenkel, C. A., & Seely, E. W. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.166 · Cited by 162
Self-citationMishra, G. D., & Kuh, D. (2012) · BMJ · doi:10.1136/bmj.e402 · Cited by 161 · cited 2×
“Other climacteric symptoms include sleep disturbance (6, 7), arthralgia (7–9), and vaginal dryness and dyspareunia (7, 10, 11).”
BackgroundNon-hormonal interventions for hot flushes in women with a history of breast cancer
Rada, G., Capurro, D., Pantoja, T., Corbalán, J., Moreno, G., Letelier, L. M., & Vera, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004923.pub2 · Cited by 160
Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000275404.76075.72 · Cited by 160
Kroenke, C. H., Caan, B. J., Stefanick, M. L., Anderson, G., Brzyski, R., Johnson, K. C., LeBlanc, E., Lee, C., La Croix, A. Z., Park, H. L., et al. (2012) · Menopause · doi:10.1097/gme.0b013e31824f606e · Cited by 159
Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials
Simon, J. A., Portman, D. J., Kaunitz, A. M., Mekonnen, H., Kazempour, K., Bhaskar, S., & Lippman, J. S. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3182a66aa7 · Cited by 158
The perimenopausal woman: Endocrinology and management
Hale, G. E., Robertson, D. M., & Burger, H. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.08.015 · Cited by 158 · cited 1×
“Menopausal transition (or perimenopause) An interval preceding the menopause characterized by variations in menstrual cycle length and bleeding pattern, mood shifts, vasomotor, and vaginal symptoms and with rising FSH levels and falling anti-Mullerian hormone and inhibin B levels, which starts during the late reproduc…”
BackgroundAbsorption of Estrogens from Vaginal Creams
Rigg, L. A., Hermann, H., & Yen, S. S. C. (1978) · New England Journal of Medicine · doi:10.1056/nejm197801262980406 · Cited by 158
Thurston, R. C., Sowers, M. R., Chang, Y., Sternfeld, B., Gold, E. B., Johnston, J. M., & Matthews, K. A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm244 · Cited by 157
Effective Treatment of Vaginal Atrophy With an Ultra–Low-Dose Estradiol Vaginal Tablet
Simon, J., Nachtigall, L., Gut, R., Lang, E., Archer, D. F., & Utian, W. (2008) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31818aa7c3 · Cited by 155
Vasomotor symptoms and cardiovascular events in postmenopausal women
Szmuilowicz, E. D., Manson, J. E., Rossouw, J. E., Howard, B. V., Margolis, K. L., Greep, N. C., Brzyski, R. G., Stefanick, M. L., O'Sullivan, M. J., Wu, C., et al. (2011) · Menopause · doi:10.1097/gme.0b013e3182014849 · Cited by 151 · cited 1×
“increased risk of major CHD and all-cause mortality (29).”
BackgroundSSRIs for Hot Flashes: A Systematic Review and Meta-Analysis of Randomized Trials
Shams, T. M., Firwana, B., Habib, F., Alshahrani, A., AlNouh, B., Murad, M. H., & Ferwana, M. S. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2535-9 · Cited by 151 · cited 1×
“All of these agents are generally well tolerated (226).”
BackgroundSelf-citationNikander, E. (2003) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(03)00232-1 · Cited by 151
Efficacy and tolerability of local estrogen therapy for urogenital atrophy
Archer, D. F. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181a95581 · Cited by 151 · cited 1×
“This may reflect an actual neutral effect due to the absence of a first-pass hepatic effect by vaginal estrogens, or that studies of women at high CVD or VTE risk are lacking (281).”
BackgroundFournier, A., Mesrine, S., Boutron‐Ruault, M., & Clavel‐Chapelon, F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6432 · Cited by 151 · cited 1×
“Observational studies also report a greater risk when EPT is started close to menopause (79, 85, 93) and with continuous rather than with cyclic regimens (78, 82, 94).”
BackgroundBreast Cancer Risk Assessment Tool
Hamid, M. H. N. A., & Aini, N. (2014) · Cited by 150
Constantine, G., Graham, S., Portman, D. J., Rosen, R. C., & Kingsberg, S. A. (2015) · Climacteric · doi:10.3109/13697137.2014.954996 · Cited by 147
Effects of Bazedoxifene/Conjugated Estrogens on the Endometrium and Bone: A Randomized Trial
Pinkerton, J. V., Harvey, J. A., Lindsay, R., Pan, K., Chines, A. A., Mirkin, S., Archer, D. F., & for the SMART-5 Investigators (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1707 · Cited by 146 · cited 7×
“In RCTs, both CEE/BZA and CEE/MPA improved sleep disturbance and time to fall asleep (185).”
BackgroundInfluentialSelf-citationBachmann, G., Lobo, R. A., Gut, R., Nachtigall, L., & Notelovitz, M. (2008) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000296714.12226.0f · Cited by 146
de Villiers, T. J., Chines, A. A., Palacios, S., Lips, P. T. A. M., Sawicki, A. Z., LEVINE, A., Codreanu, C., Kelepouris, N., & Brown, J. P. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1302-6 · Cited by 144 · cited 1×
“Although an osteoporosis trial found a 2-fold risk of VTE with BZA 20-mg therapy alone (190), 3992 Stuenkel et al Guideline on Menopause J Clin Endocrinol Metab, November 2015, 100(11):3975–4011”
BackgroundCarpenter, J. S., Storniolo, A. M., Johns, S., Monahan, P. O., Azzouz, F., Elam, J. L., Johnson, C. S., & Shelton, R. C. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-124 · Cited by 143
Biglia, N., Peano, E., Sgandurra, P., Moggio, G., Panuccio, E., Migliardi, M., Ravarino, N., Ponzone, R., & Sismondi, P. (2010) · Gynecological Endocrinology · doi:10.3109/09513591003632258 · Cited by 143 · cited 1×
“However, for women taking aromatase inhibitors, the effectivenessofwhichdependsupon blocking up to 95% of estrogen synthesis and reducing circulating estradiol levels to 1 pg/mL (250), caution is”
BackgroundBakken, K., Fournier, A., Lund, E., Waaseth, M., Dumeaux, V., Clavel‐Chapelon, F., Fabre, A., Hémon, B., Rinaldi, S., Chajes, V., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25314 · Cited by 142 · cited 1×
“Observational studies also report a greater risk when EPT is started close to menopause (79, 85, 93) and with continuous rather than with cyclic regimens (78, 82, 94).”
BackgroundCordina-Duverger, E., Truong, T., Anger, A., Sanchez, M., Arveux, P., Kerbrat, P., & Guénel, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078016 · Cited by 141 · cited 1×
“Observational studies also report a greater risk when EPT is started close to menopause (79, 85, 93) and with continuous rather than with cyclic regimens (78, 82, 94).”
BackgroundØrbo, A., Vereide, A. B., Arnes, M., Pettersen, I., & Straume, B. (2013) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12499 · Cited by 141
Simon, J. A., Lin, V. H., Radovich, C., & Bachmann, G. A. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31826d36ba · Cited by 138
Cited by
El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., Allison, M. A., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000912 · Cited by 1,219
Gravholt, C. H., Andersen, N. H., Conway, G. S., Dekkers, O. M., Geffner, M. E., Klein, K. O., Lin, A. E., Mauras, N., Quigley, C. A., Rubin, K., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0430 · Cited by 1,101
Cardiovascular Disease in Women: Clinical Perspectives
Garcia, M., Mulvagh, S. L., Bairey Merz, C. N., Buring, J. E., & Manson, J. E. (2016) · Circulation Research · doi:10.1161/circresaha.116.307547 · Cited by 1,080
“The microvasculature in women may play an important role in the predisposition of women with autoimmune diseases to develop accelerated CVD.80 The female to male ratio for rheumatoid arthritis is 2.5:1 and for systemic lupus erythematosus is 9:1.”
InfluentialThe 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
“The reason that hormone therapy was not shown to reduce hip fracture in the subset of women aged 50 to 59 years in the WHI may be partly because of the lower baseline absolute risk of fracture in women aged between 50 and 59 years who did not have established osteoporosis.(9,168)”
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Self-citation
Metadata
- Authors
- Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-11
- Volume
- 100
- Issue
- 11
- Pages
- 3975-4011
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2162957019
- Cited by
- 884
- References
- 414
- Citations by year
- 2026: 79 · 2025: 96 · 2024: 66 · 2023: 69 · 2022: 82 · 2021: 96 · 2020: 121 · 2019: 89 · 2018: 75 · 2017: 57 · 2016: 47 · 2015: 4
- FWCI
- 52.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- menopause, hormone replacement therapy, vasomotor symptoms, climacteric, postmenopausal women, cardiovascular risk screening, breast cancer risk, ospemifene, vaginal estrogen, genitourinary syndrome of menopause, vaginal moisturizers, lifestyle intervention, personalized treatment
- MeSH terms
- Contraindications, Age Factors, Breast Neoplasms, Cardiovascular Diseases, Female, Humans, Menopause, Terminology as Topic, Risk Factors, Severity of Illness Index, Estrogen Replacement Therapy, Evidence-Based Medicine, Hot Flashes, Female Urogenital Diseases, Venous Thromboembolism, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.